| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $160.6M | +849.3% |
| R&D Expense | $4.5M | -18.4% |
| SG&A Expense | $51.2M | +11.8% |
| Operating Income | -$20.2M | +77.7% |
| Net Income | -$33.8M | +57.0% |
| EPS (Basic) | -$0.14 | +58.8% |
| EPS (Diluted) | -$0.14 | +58.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $81.2M | -57.1% |
| Accounts Receivable | $8.4M | +248.2% |
| Inventory | $19.1M | +323.7% |
| Current Assets | $143.4M | -29.6% |
| Total Assets | $718.9M | +23.1% |
| Current Liabilities | $78.6M | +222.6% |
| Long-term Debt | $164.8M | +145.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.4M | +76.6% |
| Capital Expenditures | $30.1M | -41.1% |
| Investing Cash Flow | -$226.6M | -337.2% |
| Financing Cash Flow | $97.9M | +1429.5% |
| Free Cash Flow | -$43.5M | +59.9% |
| Total Liabilities |
| $247.8M |
| +162.3% |
| Stockholders' Equity | $466.3M | -4.7% |